Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Home > Pressemitteilung: Two million euros for better therapy ... MHH molecular biologist investigates the body's own repair programme in the heart muscle and receives the renowned ERC Advanced Grant ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Life relies on the storage and transmission of information. In complex organisms, this information exists in two primary ...

Hepatocytes, as the most abundant cell type in liver, are a potent source of fibrogenic ... gelatinases (MMP-2,-9) and fibroblast activation protein; [38] (3) stromelysins (MMP-3, -7, -10, 11 ...

These updated guidelines on the management of abnormal liver blood tests have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting ...

Researchers at the University of Pennsylvania have introduced lab-engineered small extracellular vesicles to target tumors in ...

(GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver ...

Scientific Advisory Board formed with internationally recognized liver and biliary tract cancer physicians to support the ...